Cláudio David

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11818511/publications.pdf

Version: 2024-02-01

1307594 1199594 13 191 7 12 citations g-index h-index papers 13 13 13 384 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Clinical effects of off-label reduced doses of Direct Oral Anticoagulants: A systematic review and meta-analysis. International Journal of Cardiology, 2022, 362, 76-82.	1.7	7
2	The sham effect of invasive interventions in chronic coronary syndromes: a systematic review and meta-analysis. BMC Cardiovascular Disorders, 2022, 22, 223.	1.7	2
3	Safety and tolerability of sacubitril-valsartan: a systematic review and meta-analysis. Expert Opinion on Drug Safety, 2021, 20, 577-588.	2.4	5
4	The Risk of Mortality Associated With Opioid Use in Patients With Acute Heart Failure: Systematic Review and Meta-analysis. Journal of Cardiovascular Pharmacology, 2021, 77, 123-129.	1.9	9
5	Antithrombotic Therapy Recommendations in the European Society of Cardiology Guidelines: How Robust Are the Randomized Controlled Trials Underpinning Them?. TH Open, 2021, 05, e125-e133.	1.4	1
6	Recommendations and levels of evidence in the guidelines of the European Society of Cardiology: current scenario and time trends. European Heart Journal - Cardiovascular Pharmacotherapy, 2020, 6, 122-124.	3.0	7
7	Influenza vaccination in patients with heart failure: a systematic review and meta-analysis of observational studies. Heart, 2020, 106, 350-357.	2.9	39
8	Aspirin in the primary prevention of cardiovascular disease on diabetic patients: Systematic review and meta-analysis. Primary Care Diabetes, 2020, 14, 213-221.	1.8	12
9	The incidence of thrombotic events with idarucizumab and andexanet alfa: A systematic review and meta-analysis. Thrombosis Research, 2020, 196, 291-296.	1.7	11
10	The association of influenza infection and vaccine with myocardial infarction: systematic review and meta-analysis of self-controlled case series. Expert Review of Vaccines, 2019, 18, 1211-1217.	4.4	27
11	Cardiotoxicity in Hematological Diseases: Are the Tyrosine Kinase Inhibitors Imatinib and Nilotinib Safe?. Cardiovascular Toxicology, 2018, 18, 431-435.	2.7	7
12	Tolerability of Angiotensin-Receptor Blockers in Patients with Intolerance to Angiotensin-Converting Enzyme Inhibitors. American Journal of Cardiovascular Drugs, 2012, 12, 263-277.	2.2	60
13	Tolerability of Angiotensin-Receptor Blockers in Patients with Intolerance to Angiotensin-Converting Enzyme Inhibitors. American Journal of Cardiovascular Drugs, 2012, 12, 263-277.	2.2	4